Globus Medical Launches ExcelsiusHub™ Navigation SystemAUDUBON, Pa., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:
GMED), a leading musculoskeletal solutions company, today announced the commercial launch of the ExcelsiusHub™ navigation system. ExcelsiusHub™ joins the expansive ecosystem of Excelsius™ technologies and is designed to elevate the standard for freehand navigation.
Globus Medical Reports Third Quarter 2024 ResultsAUDUBON, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:
GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2024.
Globus Medical to Participate in Orthopedic Trauma Association Annual MeetingAUDUBON, Pa., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:
GMED), a leading musculoskeletal solutions company, is participating in the 40th Annual Meeting of the Orthopedic Trauma Association (OTA) in Montréal, Canada, October 23—26.
Globus Medical Schedules Third Quarter Earnings Release and Conference CallAUDUBON, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:
GMED), a leading musculoskeletal solutions company, will announce its financial results for the third quarter ended September 30, 2024 after the market close on Tuesday, November 5, 2024. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.
Globus Medical Launches the Next Wave of Orthopedic Trauma SolutionsAUDUBON, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:
GMED), a leading musculoskeletal solutions company, announces the continued growth and expansion of its orthopedic trauma product portfolio.
Bragar Eagel & Squire, P.C. Is Investigating MaxLinear, Customers Bancorp, Globus, and Metagenomi and Encourages Investors to Contact the FirmNEW YORK, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against MaxLinear, Inc. (NASDAQ:
MXL), Customers Bancorp, Inc. (NYSE:
CUBI), Globus Medical, Inc. (NYSE:
GMED), and Metagenomi, Inc. (NASDAQ:
MGX). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
Bragar Eagel & Squire, P.C. Is Investigating MaxLinear, Customers Bancorp, Globus, and Domino’s and Encourages Investors to Contact the FirmNEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against MaxLinear, Inc. (NASDAQ:
MXL), Customers Bancorp, Inc. (NYSE:
CUBI), Globus Medical, Inc. (NYSE:
GMED), and Domino’s Pizza, Inc. (NSYE: DPZ). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
Bragar Eagel & Squire, P.C. Is Investigating Centuri, Medpace, Customers Bancorp, and Globus and Encourages Investors to Contact the FirmNEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Centuri Holdings, Inc (NYSE:
CTRI), Medpace Holdings, Inc. (NASDAQ:
MEDP), Customers Bancorp, Inc. (NYSE:
CUBI), and Globus Medical, Inc. (NYSE:
GMED). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
Globus Medical, Inc. (GMED) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globus Medical, Inc. (“Globus Medical” or “the Company”) (NYSE:
GMED). Investors who purchased Globus Medical securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/GMED.
GMED Investors Have Opportunity to Join Globus Medical, Inc. Securities Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Globus Medical, Inc. (“Globus” or “the Company”) (NYSE:
GMED) for violations of the securities laws.
Globus Medical Launches ADIRA™ XLIF™ Plate SystemAUDUBON, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:
GMED), a leading musculoskeletal solutions company, today announced the commercial launch of the ADIRA™ XLIF™ Plate System, the Company’s first product launch compatible across its expanded lateral interbody portfolio.
GLOBUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Globus Medical, Inc. on Behalf of Globus Stockholders and Encourages Investors to Contact the FirmNEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Globus Medical, Inc. (“Globus” or the “Company”) (NYSE:
GMED) on behalf of Globus stockholders. Our investigation concerns whether Globus has violated the federal securities laws and/or engaged in other unlawful business practices.
Globus Medical, Inc. (GMED) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Globus Medical, Inc. (“Globus Medical” or “the Company”) (NYSE:
GMED). Investors who purchased Globus Medical securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/GMED.
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Globus Medical, Inc. (GMED)
The law firm of Kirby McInerney LLP is investigating potential claims against Globus Medical, Inc. (“Globus Medical” or the “Company”) (NYSE:
GMED). The investigation concerns whether Globus Medical and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Globus Medical, Inc. (“Globus Medical” or the “Company”) (NYSE:
GMED) investors concerning the Company’s possible violations of the federal securities laws.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Globus Medical, Inc. (“Globus Medical” or the “Company”) (NYSE:
GMED) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz Announces Investigation of Globus Medical, Inc. (GMED) on Behalf of Investors
The Law Offices of Frank R. Cruz announces an investigation of Globus Medical, Inc. (“Globus Medical” or the “Company”) (NYSE:
GMED) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Globus Medical Reports Second Quarter 2024 ResultsAUDUBON, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:
GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2024.
Globus Medical Receives FDA 510(k) Clearance for ExcelsiusFlex™ and ACTIFY™ 3D Total Knee SystemAUDUBON, Pa., July 17, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:
GMED), a leading musculoskeletal solutions company, today announced it recently received 510(k) clearance by the U.S. Food and Drug Administration (FDA) for ExcelsiusFlex™ with Total Knee Arthroplasty (TKA) application. This new robotic navigation platform joins the already best-in-class Excelsius™ ecosystem, designed to offer surgeons control, resection accuracy, and procedural flexibility in Total Knee Arthroplasty. Additionally, ACTIFY™ 3D Total Knee System, the latest in implant technology that will pair with ExcelsiusFlex™, has also received 510(k) clearance.
Globus Medical Schedules Second Quarter Earnings Release and Conference CallAUDUBON, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:
GMED), a leading musculoskeletal solutions company, will announce its financial results for the second quarter ended June 30, 2024 after the market close on Tuesday, August 6, 2024. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.
Globus Medical Reports First Quarter 2024 ResultsAUDUBON, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:
GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2024.
Globus Medical Schedules First Quarter Earnings Release and Conference CallAUDUBON, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:
GMED), a leading musculoskeletal solutions company, will announce its financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, May 7, 2024. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.
Globus Medical Reports Fourth Quarter and Full Year 2023 ResultsAUDUBON, Pa., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:
GMED), a leading musculoskeletal technology company, today announced its financial results for the fourth quarter and year ended December 31, 2023.
Globus Medical Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference CallAUDUBON, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:
GMED), a leading musculoskeletal solutions company, will announce its financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Tuesday, February 20, 2024. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.
